文献速递主动脉疾病

编辑推荐——二甲双胍处方与腹主动脉瘤患者手术修复及破裂相关死亡率联合发生率降低相关

Editor's Choice - Metformin Prescription is Associated with a Reduction in the Combined Incidence of Surgical Repair and Rupture Related Mortality in Patients with Abdominal Aortic Aneurysm.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2018-08-30

这项在澳大利亚三座城市开展的前瞻性队列观察研究纳入1080例无症状未修复的腹主动脉瘤(AAA)患者,评估二甲双胍处方与AAA相关临床事件(择期/急诊修复或AAA相关死亡)的关联。结果显示,合并糖尿病且处方二甲双胍者较无糖尿病者AAA事件发生率更低(校正HR 0.63,95%CI 0.44–0.93),而未处方二甲双胍的糖尿病患者则无此关联(校正HR 1.15,95%CI 0.83–1.59)。作者认为二甲双胍可能减少糖尿病患者临床重要的AAA事件,但需随机对照试验证实。

要点

  • 合并糖尿病且处方二甲双胍的患者AAA事件发生率低于无糖尿病者(校正HR 0.63,95%CI 0.44–0.93)。
  • 合并糖尿病但未处方二甲双胍者与无糖尿病者相比AAA事件发生率无显著差异(校正HR 1.15,95%CI 0.83–1.59)。
  • 作者结论为二甲双胍可能减少糖尿病患者的临床重要AAA事件,需随机对照试验证实。

核心结论

  • 作者认为,二甲双胍处方可能减少合并糖尿病患者的临床重要AAA事件,但未处方二甲双胍的糖尿病患者未观察到该关联。
  • 作者指出需要随机对照试验来明确二甲双胍是否能减少无糖尿病的小AAA患者的AAA相关临床事件。

研究设计与样本

  • 这是一项在澳大利亚三座城市开展的前瞻性队列观察研究,设计目的是研究临床事件的危险因素,而非仅聚焦二甲双胍。
  • 从四家中心的医院门诊和监测项目招募无症状、未修复、直径≥30 mm的AAA患者,共1080例,初始AAA直径均值(标准差)为46.1(11.3)mm。
  • 随访均值(标准差)为2.5(3.1)年,随访至发生AAA事件(n=454)、死亡(n=176)、失访(n=128)或完成当前随访(n=322)。
  • 主要结局为需要AAA修复或AAA相关死亡(AAA事件),采用Kaplan-Meier分析和Cox比例风险分析评估二甲双胍处方与AAA事件的关联。

主要发现

  • 合并糖尿病且处方二甲双胍的患者与无糖尿病者相比,AAA事件发生率更低(校正HR 0.63,95%CI 0.44–0.93)。
  • 合并糖尿病但未处方二甲双胍的患者与无糖尿病者相比,AAA事件发生率无显著差异(校正HR 1.15,95%CI 0.83–1.59)。
  • 在仅限初始AAA直径≤50 mm的患者以及AAA事件前至少随访6个月的患者中进行的敏感性分析,结果相似。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Currently there is no drug therapy for abdominal aortic aneurysm (AAA) and most previous investigations have focused on imaging rather than clinical outcomes. The aim of this study was to assess whether AAA related clinical events were lower in patients prescribed metformin. METHODS: This was a prospective cohort observational study performed in three cities in Australia, which was designed to study risk factors for clinical events not simply to focus on metformin. Patients with an asymptomatic unrepaired AAA of any diameter ≥30 mm were recruited from hospital outpatient clinics and surveillance programs run at four centres. The main outcome was the requirement for AAA repair or AAA related mortality (AAA events). The association between metformin prescription and AAA events was assessed using Kaplan-Meier analysis and Cox proportional hazard analysis. RESULTS: Patients (1,080) with a mean (SD) initial AAA diameter of 46.1 (11.3) mm were followed for a mean (SD) of 2.5 (3.1) years until an AAA event (n = 454), death (n = 176), loss to follow up (n = 128), or completion of current follow up (n = 322). Patients with diabetes who were prescribed metformin (adjusted HR 0.63, 95% CI 0.44-0.93), but not patients with diabetes who were not prescribed metformin (adjusted HR 1.15, 95% CI 0.83-1.59), had a lower incidence of AAA events compared with those without diabetes. Findings were similar in sensitivity analyses restricted to patients with an initial AAA diameter ≤50 mm and patients with a minimum follow up of six months before an AAA event. CONCLUSIONS: These findings suggest that clinically important AAA events may be reduced in patients with diabetes who are prescribed metformin, but not those with diabetes receiving other treatments. A randomised controlled trial is needed to definitively test whether metformin reduces AAA related clinical events in patients with small AAAs who do not have diabetes.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Golledge J, Morris DR, Pinchbeck J, et al. Editor's Choice - Metformin Prescription is Associated with a Reduction in the Combined Incidence of Surgical Repair and Rupture Related Mortality in Patients with Abdominal Aortic Aneurysm. Eur J Vasc Endovasc Surg. 2018. PMID: 30174271. doi:10.1016/j.ejvs.2018.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。